Posso ottenerlo?
Sì, se un medico ritiene che sia adatto a Lei. Semaglutide è autorizzato nell’UE e può essere prescritto dopo una valutazione medica.
SemaglutideSolo su prescrizione
Consulto medico online per Semaglutide.
Un medico autorizzato dall'UE esamina il Suo caso e, se idoneo, rilascia una prescrizione elettronica valida in qualsiasi farmacia dell'UE ai sensi della direttiva 2011/24/UE.
- Taken just once a week
- Curbs appetite and cravings
- Studied in large clinical trials for weight loss
Inizia consultoInizia consulto · 25 €/mese
Rimborso completo se una valutazione non viene approvata · Il farmaco, se prescritto, viene dispensato e pagato separatamente in farmacia.
IN PAROLE SEMPLICI
Cos’è Semaglutide e come ottenere un trattamento
Semaglutide è un medicinale somministrato con un’iniezione sotto la pelle una volta alla settimana. Imita un ormone intestinale naturale chiamato GLP-1 che il Suo corpo produce dopo aver mangiato. In questo modo si sente sazio prima e più a lungo, e la maggior parte delle persone finisce per mangiare meno. Nell’UE il prodotto autorizzato per il controllo del peso è Wegovy, usato insieme a una dieta con meno calorie e più attività fisica. Lo stesso principio attivo viene venduto anche come Ozempic, ma si tratta di un prodotto distinto, autorizzato per il diabete di tipo 2 e non per il controllo del peso.
Semaglutide è autorizzato per l’uso nell’UE dal 6 gennaio 2022. Un medico abilitato può quindi prescriverlo quando è clinicamente adatto a Lei.
Maggiori informazioni sui peptidi su Peptidepedia.
Cosa posso prendere al suo posto?
I nostri medici esaminano ogni opzione per Perdita di peso e consigliano quella più adatta alla Sua storia clinica e ai Suoi obiettivi.
Veda tutte le opzioni per Perdita di pesoCosa mostrano gli studi?
Tutti gli studi su Semaglutide sono elencati qui sotto con il numero di registro, il numero di partecipanti e l’indicazione se i risultati sono stati sottoposti a revisione paritaria o provengono da un annuncio dell’azienda.
Vada agli studiEVIDENZE VERIFICATE
Semaglutide: guida alle evidenze e alla regolamentazione.
CHE COS’È
Come agisce
It copies GLP-1, a hormone the gut releases after a meal, which reduces appetite and slows how quickly the stomach empties.
- GLP-1
FASE DI SVILUPPO
Medicinale autorizzato nell’UE
Registro degli studi1 studi registrati
Ogni identificativo NCT rimanda al record ClinicalTrials.gov. Una comunicazione dei risultati non equivale a una pubblicazione sottoposta a revisione paritaria.
| STUDIO / NCT | POPOLAZIONE | PARTECIPANTI | STATO | RISULTATO / COMPLETAMENTO |
|---|---|---|---|---|
| STEP 1NCT03548935 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related condition, without type 2 diabetes; all received lifestyle counselling | 1,961 | Con risultati | 2021-03-18 |
Che cosa hanno riportato gli studi
I risultati sono separati per fonte e grado di evidenza, così i dati scientifici non vengono confusi con gli annunci del produttore.
Revisione paritaria
Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 (PMID 33567185)| DOSE O GRUPPO | VARIAZIONE MEDIA DEL PESO | SETTIMANE |
|---|---|---|
| 2.4 mg once weekly | −14.9% | 68 |
| Placebo | −2.4% | 68 |
Everyone in the trial also followed a reduced-calorie diet and increased physical activity, people with type 2 diabetes were excluded, and the study measured weight only up to week 68.
SEGNALI DI SICUREZZA IDENTIFICATI
Che cosa è stato segnalato con Semaglutide.
Nausea
Reported by 38.3% of people on semaglutide 2.4 mg versus 14.0% on placebo across the pooled STEP 1–4 phase 3 programme assessed by the EMA.
Diarrhoea
Reported by 26.8% on semaglutide 2.4 mg versus 14.3% on placebo in the same pooled programme.
Vomiting
Reported by 21.8% on semaglutide 2.4 mg versus 5.7% on placebo in the same pooled programme.
Constipation
Reported by 21.8% on semaglutide 2.4 mg versus 10.2% on placebo in the same pooled programme.
Gallbladder problems
Gallbladder-related events were reported by 2.5% on semaglutide 2.4 mg versus 1.6% on placebo, mainly gallstones (1.6% versus 1.1%).
Acute pancreatitis
Independently confirmed in 4 people (0.2%) on semaglutide 2.4 mg and 1 person (under 0.1%) on placebo in the pooled programme.
Stopping treatment because of side effects
5.7% of people on semaglutide 2.4 mg stopped treatment because of side effects versus 3.0% on placebo, mostly because of stomach and bowel symptoms.
25 €/mese (fatturati 25 € ogni 28 giorni)Avvia una consulenza medica
FormaPenna per iniezione pre-riempita
FrequenzaUna volta alla settimana
RisultatiGradual, over ~16 weeks
Quanto paghi a Hi-Doctor25 €/mese (fatturati 25 € ogni 28 giorni)
IN 60 SECONDI
Semaglutide in sintesi
- A GLP-1 receptor agonist, given as an injection under the skin from a pen.
- Adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition.
- One injection under the skin, once a week, on the same day each week.
- Nausea and vomiting are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
Sul trattamento
Che cos'è Semaglutide?
Commercializzato anche come Ozempic, Wegovy.
Principio attivo: Semaglutide · Dosaggi: 0.25 – 2.4 mg / week
Semaglutide is a GLP-1 receptor agonist — a medication that mimics a natural hormone your gut releases after eating. It reduces appetite, slows gastric emptying and helps maintain sustained weight loss when combined with supervised nutrition and activity changes.
It's prescribed alongside changes to diet and activity, as part of a medically supervised plan — not on its own, and not as a shortcut. A licensed EU doctor decides whether it's appropriate and safe for you.
COME AGISCE
Che cosa fa Semaglutide nel tuo corpo
Semaglutide may reduce appetite and slow how quickly your stomach empties, so you tend to feel full sooner and eat less. Effects build gradually and vary from person to person.
It copies a natural gut hormone
Semaglutide is a close copy of GLP-1, a hormone your gut releases after you eat. It shares about 94% of the structure of the natural hormone, so it fits the same docking points on cells, but it is built to last much longer in the body.
It acts on appetite centres
Once attached to those docking points, semaglutide signals the parts of the brain that control hunger, including the hypothalamus and brainstem. In clinical studies people reported feeling full sooner, staying full for longer, feeling less hungry, and having fewer and weaker food cravings.
Eating less drives the change
Because appetite falls, most people take in fewer calories without consciously trying, and that gap is what produces weight change over months. Semaglutide also slightly slows how fast the stomach empties early after a meal, and prompts insulin release only when blood sugar is high.
Come aiuta
Three ways it supports weight loss.
Eases appetite
Acts on hunger signals, so many people feel satisfied with less food.
Slows digestion
Food stays in your stomach longer, so you tend to feel full for longer.
Part of a plan
Prescribed alongside support for diet and activity — never as a standalone fix.
Cosa aspettarsi
A gradual, supervised start.
The dose is increased slowly over 16 weeks to help your body adjust and to ease side effects. Your doctor sets your exact schedule.
- Weeks 1–4 · Lowest dose
- Weeks 5–16 · Step up gradually
- Month 4+ · Maintenance dose
- Ongoing · Regular check-ins
Typical escalation
- Weeks 1–40.25 mg / week
- Weeks 5–80.5 mg / week
- Weeks 9–121 mg / week
- Weeks 13–161.7 mg / week
- Maintenanceup to 2.4 mg / week
Il Suo piano è personale
Questi passaggi sono solo indicativi. Il medico adatta il piano alla Sua risposta e tolleranza — e può scrivergli in qualsiasi momento.
NELLA VITA QUOTIDIANA
Usare Semaglutide nella vita quotidiana
One injection, same day weekly
Semaglutide for weight management is injected under the skin once a week, at any time of day, with or without food. Most people pick a fixed day and set a reminder, because the weekly rhythm is easy to lose track of.
Choose and rotate injection sites
The approved sites are the abdomen, the thigh and the upper arm. The site can be changed from week to week. Rotating between sites is standard practice for injections under the skin and helps avoid repeated irritation in one spot.
Use a fresh needle every time
Attach a new needle for each injection and remove it afterwards, storing the pen without a needle attached. The product information says this helps prevent blocked needles, contamination, infection, leaking solution and inaccurate dosing. Compatible needles are 30G, 31G or 32G.
Check the liquid before injecting
Look at the solution first. It should be clear and colourless. The product information says not to use the pen if the liquid looks otherwise, or if it has been frozen at any point. Pens must never be shared between people.
Follow the pack instructions exactly
Each pen type has its own instructions for use inside the carton, and the product information asks patients to read them carefully before the first injection. With a single-dose pen you press it firmly against the skin until the yellow bar stops moving.
If you miss a dose
Take a missed dose as soon as possible, as long as fewer than five days have passed. If more than five days have gone by, skip it and take the next dose on the normal day. Ask the prescriber before restarting after several missed doses.
Moving your weekly dosing day
The day of the week can be changed if needed, provided at least three days, meaning more than 72 hours, separate one dose from the next. After moving to a new day, carry on with the once-weekly pattern from there.
Storing the pen correctly
Before first use, keep the pen in the fridge between 2°C and 8°C, away from the cooling element, and never freeze it. Keep the cap on to protect it from light. After first use a FlexTouch pen keeps for six weeks below 30°C.
Sicurezza prima di tutto
La sicurezza, per intero.
Semaglutide è un farmaco efficace — e, come ogni farmaco, comporta dei rischi. Il medico verifica tutto questo prima di prescrivere. Ecco il quadro onesto, non solo una rassicurazione.
Effetti indesiderati, per frequenza
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe, persistent stomach pain, often spreading through to the back
- Sudden loss of vision, including partial loss in one eye
- Swelling of the face, lips, tongue or throat, or trouble breathing
- Severe stomach pain with bloating, vomiting and no bowel movements
- Pain under the right ribs with fever or yellowing skin
- Vomiting or diarrhoea so severe that you cannot keep fluids down
- Shakiness, confusion or sweating if you also take insulin or a sulfonylurea
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea)
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Stomach pain
- Headache
- Tiredness
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Dizziness
- Altered sense of taste
- Unusual skin sensations such as tingling or numbness
- Indigestion, heartburn or acid reflux
- Inflammation of the stomach lining (gastritis)
- Burping, wind or a bloated stomach
- Gallstones
- Hair loss
- Reactions where the injection was given
- Low blood sugar, in people who also have type 2 diabetes
- Worsening of diabetic eye disease, in people with type 2 diabetes
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Inflammation of the pancreas (acute pancreatitis)
- The stomach emptying more slowly than usual
- A faster heart rate
- Low blood pressure
- Feeling dizzy on standing up (orthostatic hypotension)
- Raised amylase and lipase, two pancreatic enzymes, in blood tests
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Severe allergic reaction affecting the whole body (anaphylaxis)
- Swelling of the face, lips, tongue or throat (angioedema)
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Sudden loss of vision caused by damage to the optic nerve
Reported, frequency not known
frequency not known
reported after the medicine was licensed; how often is not established
- Blockage of the bowel (intestinal obstruction)
Adulti con obesità (BMI ≥30) o con sovrappeso (BMI ≥27) più almeno una condizione correlata al peso come diabete di tipo 2, ipertensione o dislipidemia.
- Autoiniezione una volta a settimana nella coscia, nell'addome o nella parte superiore del braccio.
- La dose viene aumentata gradualmente (0,25 mg → 0,5 → 1,0 → 1,7 → 2,4 mg) nell'arco di 16 settimane per limitare gli effetti collaterali gastrointestinali.
- In combinazione con dieta e attività fisica — semaglutide non sostituisce il cambiamento dello stile di vita.
CHI NON DEVE ASSUMERLO E CHI RICHIEDE CAUTELA
- You have ever had an allergic reaction to semaglutide or any ingredient in the pen
- You are pregnant, planning a pregnancy within the next two months, or breastfeeding
- You have type 1 diabetes, because semaglutide is not a substitute for insulin
- You already take another GLP-1 receptor agonist, as the combination has not been evaluated
- You take another prescription weight-management medicine at the same time
- You have severe kidney impairment, including end-stage kidney disease
- You have severe liver impairment
- You have severe gastroparesis, a condition where the stomach empties very slowly
- You have congestive heart failure classed as New York Heart Association class IV
- You have type 2 diabetes with uncontrolled or unstable diabetic eye disease
Quando cercare assistenza urgente
In caso di sintomi gravi, improvvisi o inattesi, chiami il numero di emergenza locale o si rechi al pronto soccorso più vicino. Poi informi il medico tramite la chat del Suo account.
Farmaci e sostanze che interagiscono
| FARMACO O SOSTANZA | COSA PUÒ ACCADERE | COSA FA IL MEDICO |
|---|---|---|
| Warfarin and other coumarin blood thinners | Cases of a reduced INR clotting measure have been reported alongside semaglutide. | Prescriber arranges more frequent INR blood tests when semaglutide is started. |
| Insulin | Combined with semaglutide in type 2 diabetes, the risk of low blood sugar rises. | Prescriber may lower the insulin dose at the start and monitor blood sugar. |
| Sulfonylureas (e.g. gliclazide) | Also raise the risk of low blood sugar when taken alongside semaglutide. | Prescriber may reduce the sulfonylurea dose when semaglutide is introduced. |
| Oral medicines needing fast absorption | Semaglutide slows stomach emptying, which could in principle affect how they are absorbed. | Prescriber uses caution and reviews whether timing or monitoring needs changing. |
| Combined oral contraceptives | No clinically relevant change; levonorgestrel exposure rose 20%, ethinylestradiol was unaffected. | No dose change needed. Contraception is advised while taking semaglutide. |
| Paracetamol | Peak levels fell 23% with semaglutide 1 mg, but total exposure was unchanged. | No dose adjustment of paracetamol is required. |
| Atorvastatin | Peak level fell 38% but overall exposure was unchanged, judged not clinically relevant. | No dose adjustment is required. |
| Digoxin and metformin | Semaglutide did not change overall exposure or peak levels of either medicine. | No dose adjustment is required. |
Fai valutare il tuo caso da un medicoÈ esattamente ciò che il medico verifica prima di prescrivere qualsiasi cosa.
Leggi il riepilogo completo sulla sicurezza di SemaglutideEVIDENZE
Che cosa hanno rilevato gli studi clinici
The weight-management evidence for semaglutide comes from the STEP trial programme, and its cardiovascular evidence comes from the SELECT trial.
1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1. The placebo group changed -2.4%.
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1. The placebo group lost 2.6 kg. Estimated treatment difference -12.7 kg (95% CI -13.7 to -11.7).
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity1,961 adults with overweight or obesity, without diabetes · 68 weeks
STEP 1, versus 12.0% on placebo. Half the semaglutide group (50.5%) lost 15% or more.
Fonte: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or ObesityAdults who completed a 20-week run-in up to the 2.4 mg dose · 48 weeks, from week 20 to week 68
STEP 4. Those switched to placebo regained weight. Difference -14.8 percentage points.
Fonte: STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance17,604 adults aged 45+ with existing cardiovascular disease and BMI 27+, no diabetes
SELECT. Events occurred in 6.5% on semaglutide versus 8.0% on placebo.
Fonte: SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesThese figures are averages across large groups, not a forecast for any one person. In STEP 1 the middle of the group lost close to 15% of their starting weight over 68 weeks, but individual results ranged from substantial loss to almost none, and everyone in the trial was also following a reduced-calorie diet and increased physical activity. STEP 4 is the important counterpoint: weight came back when treatment stopped, so this is a long-term treatment rather than a short course, and whether it is right for you is a decision for the prescribing doctor.
ALTERNATIVE
Weight-management medicines authorised in the EU
| FARMACO | COME SI ASSUME | OGNI QUANTO | INTERVALLO DI DOSE ABITUALE | INDICAZIONE AUTORIZZATA NELL'UE | EVIDENZA PRINCIPALE |
|---|---|---|---|---|---|
| Semaglutide | Iniezione settimanale | Una volta a settimana | 0.25-2.4 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition. | STEP 1: mean -14.9% body weight at 68 weeks |
| Tirzepatide | Iniezione settimanale | Una volta a settimana | 2.5-15 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 or above with a weight-related condition. Also authorised for type 2 diabetes. | EMA: about 15% mean weight reduction over 72 weeks |
| Liraglutide | Iniezione quotidiana | Una volta al giorno | 0.6-3.0 mg | Weight management alongside a reduced-calorie diet and more physical activity, in adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition. | EMA: 7.5% mean weight reduction versus 2.3% on placebo |
| Orlistat | Capsula orale | Fino a tre volte al giorno con i pasti | 120 mg per meal | Treatment of obesity alongside a mildly reduced-calorie diet, in patients with a BMI of 30 or above, or above 28 with associated risk factors. | EMA: mean 6.1 kg lost over one year versus 2.6 kg |
Non sai quale sia adatto al tuo caso? Il medico esamina la tua storia clinica e te lo dice.
Inizia consulto · 25 €/meseACCESSO E COSTI
Come ottenere Semaglutide e quanto costa
Semaglutide is a prescription-only medicine everywhere in the EU, so it cannot be bought over the counter in any of these countries. Whether the national health system pays for it when it is prescribed for weight management is decided country by country, and in most of these markets it is not covered, meaning the patient pays.
Quanto paghi a Hi-Doctor
25 €/mese (fatturati 25 € ogni 28 giorni)
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.
Quanto addebita la farmacia
Hi-Doctor non vende, non detiene e non dispensa farmaci e non ne stabilisce il prezzo. Il farmaco si paga separatamente in farmacia e l'importo dipende dal paese, dalla confezione, dalla disponibilità di un generico e dalla rimborsabilità. La banca dati ufficiale collegata nella tabella pubblica il prezzo autorizzato in vigore.
| PAESE | REGIME DI FORNITURA | RIMBORSATO DAL SISTEMA SANITARIO? | FONTE UFFICIALE |
|---|---|---|---|
| Spagna | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | AEMPS CIMA |
Mostra gli altri paesi
| Germania | Medicinale soggetto a prescrizione medica | Excluded by law from statutory cover | PharmNet.Bund AMIce |
|---|---|---|---|
| Francia | Medicinale soggetto a prescrizione medica | Restricted — see national criteria | Base de données publique des médicaments |
| Italia | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | AIFA Medicinali |
| Paesi Bassi | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | CBG-MEB Geneesmiddeleninformatiebank |
| Portogallo | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | INFARMED Infomed |
| Belgio | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Irlanda | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | HPRA Find a Medicine |
| Austria | Medicinale soggetto a prescrizione medica | Restricted — see national criteria | BASG Medikamente Info Austria |
| Polonia | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | Rejestr Produktów Leczniczych |
PREZZI
Paghi solo se il trattamento è approvato.
25 €/mese per il controllo del peso o 15 €/mese (fatturati 45 € ogni 90 giorni) per la crescita dei capelli. Per la salute sessuale è disponibile una consultazione una tantum da 35 €.
Perdita di peso
PIANO CONTINUATIVO
25 €/mese
Fatturati 25 € ogni 28 giorni · annulli quando vuoi
Ciclo di trattamento di 28 giorni
Per un trattamento continuativo e rinnovi valutati dal Suo medico.
Rinnovi valutati dal Suo medico
Inizia consulto
Rimborso completo se una valutazione non viene approvata
COSA È INCLUSO
- Primo consulto incluso
- Rinnovi valutati dal Suo medico
- Assistenza continuativa con il Suo medico
- Può disdire in qualsiasi momento
Rimborso completo se una valutazione non viene approvata
Se una valutazione non viene approvata, rimborsiamo la quota di 25 € di quel periodo e annulliamo il piano.
Nota: Il farmaco, se prescritto dal medico, viene pagato separatamente in farmacia al prezzo stabilito. Hi-Doctor non vende farmaci.
COME DECIDE IL MEDICO
Il tuo caso lo valuta un medico abilitato, non un algoritmo
Un medico abilitato nell'UE legge il tuo questionario e risponde in meno di 2 ore in media.
Se il medico decide che non è sicuro prescrivere, il costo della consulenza viene rimborsato per intero.
Il follow-up avviene nella chat privata del tuo account, nel rispetto del GDPR. Niente WhatsApp, niente SMS.
DOMANDE FREQUENTI
Domande su Semaglutide.
ALTRI TRATTAMENTI PERDITA DI PESO
Esplora i trattamenti correlati.
FONTI
Da dove provengono queste informazioni
- 01
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Wegovy: Annex I Summary of Product Characteristics (EU product information) — European Medicines Agency, 2026
- 03
Wegovy (semaglutide): European Public Assessment Report overview — European Medicines Agency, 2026
- 04
Ozempic (semaglutide) solution for injection: Summary of Product Characteristics, type 2 diabetes indication — electronic medicines compendium (emc), 2026
- 05
STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (Wilding JPH et al., 384:989-1002), 2021
- 06
STEP 4: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance — JAMA (Rubino D et al., 325:1414-1425), 2021
- 07
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — New England Journal of Medicine (Lincoff AM et al., 389:2221-2232), 2023
- 08
Semaglutide (Wegovy, Ozempic, Rybelsus): NHS medicines A to Z — National Health Service (UK), 2026
- 09
Wegovy FlexTouch: authorisation and supply classification record — AEMPS CIMA (Spain), 2026
- 10
Ficha técnica Wegovy 2,4 mg FlexTouch: EU Summary of Product Characteristics, section 4.8 adverse reaction table — AEMPS CIMA (Spain), 2026
- 11
Situación de financiación de medicamentos: Wegovy 2,4 mg, national code 758089 — Ministerio de Sanidad (Spain), 2023
- 12
G-BA implements the statutory prescribing exclusion for the weight-loss medicine Wegovy — Gemeinsamer Bundesausschuss (Germany), 2024
- 13
Obésité: de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées — Assurance Maladie / ameli.fr (France), 2026
- 14
Wegovy niet vergoeden uit het basispakket: GVS advice on semaglutide for obesity — Zorginstituut Nederland, 2024
- 15
Medicines to treat obesity: reimbursement status of semaglutide in Ireland — Health Service Executive (Ireland), 2026
- 16
Obwieszczenie Ministra Zdrowia: wykaz refundowanych leków (pharmacy reimbursement list) — Ministerstwo Zdrowia (Poland), 2026
- 17
Rejestr Produktów Leczniczych: Wegovy (semaglutidum) registration record, ATC A10BJ06 — Rejestry Medyczne / e-Zdrowie (Poland), 2026
- 18
Behandlungspfad Übergewicht & Adipositas: case-by-case consideration of weight-reduction medicines — Dachverband der österreichischen Sozialversicherung (Austria), 2026
- 19
Warning on falsified GLP-1 receptor agonists: prescription status and pharmacy-only supply in Austria — Bundesamt für Sicherheit im Gesundheitswesen (BASG, Austria), 2026
- 20
Nieuwigheden geneesmiddelen: Wegovy commercialised in Belgium, not reimbursed for obesity — Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI/CBIP), 2025
- 21
Wegovy FlexTouch: INFARMED market authorisation notice and semaglutide safety communication — INFARMED, I.P. (Portugal), 2026
- 22
Nuovi farmaci per il diabete e l'obesità: AIFA guide to responsible use, Wegovy class C classification — Agenzia Italiana del Farmaco (AIFA), 2026
- 23
Mounjaro (tirzepatide): European Public Assessment Report overview — European Medicines Agency, 2026
- 24
Saxenda (liraglutide): European Public Assessment Report overview — European Medicines Agency, 2026
- 25
Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 26
Xenical (orlistat): European Public Assessment Report overview — European Medicines Agency, 2026
Revisionato dal team medico di Hi-Doctor · Ultima revisione 2026-07-27 · Prossima revisione prevista il 2027-07-27
Questa pagina contiene informazioni su un farmaco: non è una raccomandazione ad assumerlo né sostituisce una visita medica. Solo un medico abilitato che abbia esaminato la tua storia clinica può stabilire se un trattamento è adatto a te.
Scopra se fa per Lei
Verifichi se Semaglutide è appropriato per Lei.
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.